Trial Profile
Tagraxofusp-Based Therapy to Eradicate Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Tagraxofusp (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 10 Apr 2023 Planned End Date changed from 3 Mar 2026 to 3 Aug 2026.
- 10 Apr 2023 Planned primary completion date changed from 3 Mar 2025 to 3 Aug 2025.